However, the current therapeutic efficacy is still limited, and adverse effects are commonly experienced. Based on the crucial role of hypocholinergic function on dementia mentioned earlier, current anti-dementia drugs are targeted at the enhancement of cholinergic function.
Therefore, it has gained much attention.ĭementia, especially age-related dementia, is associated with many factors including forebrain and hippocampal atrophy, acetylcholine (ACh) reduction, cholinergic hypofunction, basal forebrain cholinergic neuron degeneration, neurotrophic signaling reduction and excess oxidative stress. This condition produces a great impact on the healthcare budget and social care. The total number of people with dementia worldwide in 2010 was estimated at 35.6 million and is projected to nearly double every 20 years to 65.7 million in 2030 and 115.4 million in 2050. The importance of dementia, a condition of memory and intellectual impairment, is increasing along with the increase in the older population. However, further investigations on the subchronic toxicity of CP1 and drug interactions are required. These results suggested that CP1 might improve memory via enhanced cholinergic function and decreased neurodegeneration and oxidative stress.ConclusionsCP1 is a potential novel food supplement for dementia. At the end of the study, neuronal density, acetylcholinesterase (AChE) activity, oxidative stress status and the activation of MAPK cascades in the hippocampus were determined.ResultsEnhanced memory, increased neuronal density, decreased AChE activity and decreased oxidative stress status together with activated pERK1/2 were observed in the hippocampus of CP1-treated rats. Spatial memory was assessed in all rats every 7 days throughout the 14 day-experimental period. Therefore, we aimed to determine the effect of the combined extract of Cyperus rotundus and Zingiber officinale (CP1) on the improvement of age-related dementia in rats with AF64A-induced memory deficits.MethodsMale Wistar rats weighing 180-200 g were orally given CP1 at doses of 100, 200 and 300 mg.kg-1 BW for a period of 14 days after bilateral intracerebroventricular administration of AF64A. BackgroundCurrently, food supplements to improve age-related dementia are required.
0 kommentar(er)
